Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients.

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Takehiko MoriShinichiro Okamoto

Abstract

We previously reported the efficacy of oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis. The purpose of this study was to evaluate whether the further shortening of the duration of oral cryotherapy could minimize its side effects while sparing its efficacy. Seventeen consecutive recipients of allogeneic hematopoieic stem cell transplant conditioned with high-dose melphalan in combination with fludarabine alone or with fludarabine and additional radiation were enrolled in the study. The severity of stomatitis was graded according to the National Cancer Institute-Common Toxicity Criteria. Patients were kept on oral cryotherapy shortly before, during, and for additional 30 min after the completion of melphalan administration (60-min oral cryotherapy). Patients who were also enrolled in our previous study received the same type of oral cryotherapy but for additional 90 min after the completion of melphalan administration (120-min oral cryotherapy), and they served as controls. Only 2 (11.8%) of 17 patients receiving 60-min oral cryotherapy and 2 (11.1%) of 18 patients receiving 120-min oral cryotherapy developed grade 2 or 3 stomatitis, respectively. The difference between groups was not statistically s...Continue Reading

References

Mar 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D J MahoodN L Gusa
Jul 1, 1994·European Journal of Cancer. Part B, Oral Oncology·S CascinuG Catalano
Jun 15, 1996·Lancet·G MeloniF Mandelli
Apr 27, 2004·Cancer·Edward B RubensteinUNKNOWN International Society for Oral Oncology
Jan 26, 2005·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Yoshinobu AisaShinichiro Okamoto

❮ Previous
Next ❯

Citations

Mar 30, 2007·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Anncarin SvanbergKerstin Ohrn
Sep 25, 2012·Journal of Investigative and Clinical Dentistry·Omar KujanSalah Sakka
Jul 1, 2010·National Journal of Maxillofacial Surgery·Afshan BeySarwat H Hashmi
Nov 12, 2013·Journal of Pain and Symptom Management·Kunal C KadakiaCharles L Loprinzi
Oct 22, 2008·Seminars in Oncology·Axel GrotheyUNKNOWN North Central Cancer Treatment Group
Jul 28, 2010·Journal of Clinical Nursing·Anncarin SvanbergGunnar Birgegård
Nov 28, 2014·Clinical Journal of Oncology Nursing·June EilersLee Ann Johnson
May 1, 2016·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Naoto OkadaKeisuke Ishizawa
Dec 24, 2015·The Cochrane Database of Systematic Reviews·Philip RileyMartin G McCabe
Sep 6, 2006·Bone Marrow Transplantation·T MoriS Okamoto
Apr 15, 2011·The Cochrane Database of Systematic Reviews·Helen V WorthingtonTasneem Khalid
Jul 16, 2019·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Yin LuHaifang Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.